A carregar...
SAT-477 Melanoma Treated with Pembrolizumab Leading to Thyroiditis and Subsequent Hypothyroidism
Background: Pembrolizumab (PD-1) is an immune checkpoint inhibitor used for treating melanoma and has been associated endocrine immune-related adverse events. Case Presentation: 76-year-old Caucasian male presented for evaluation of abnormal thyroid labs. Significant co-morbidities included recurren...
Na minha lista:
| Publicado no: | J Endocr Soc |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208300/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.983 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|